MAP-Kinase-Driven Hematopoietic Neoplasms: A Decade of Progress in the Molecular Age
Overview
Affiliations
Mutations in members of the mitogen-activated protein kinase (MAPK) pathway are extensively studied in epithelial malignancies, with mutations being one of the most common alterations activating this pathway. However, mutations are overall quite rare in hematological malignancies. Studies over the past decade have identified high-frequency , , and other kinase alterations in two groups of MAPK-driven hematopoietic neoplasms: hairy cell leukemia (HCL) and the systemic histiocytoses. Despite HCL and histiocytoses sharing common molecular alterations, these are phenotypically distinct malignancies that differ in respect to clinical presentation and suspected cell of origin. The purpose of this review is to highlight the molecular advancements over the last decade in the histiocytic neoplasms and HCL and discuss the impact these insights have had on our understanding of the molecular pathophysiology, cellular origins, and therapy of these enigmatic diseases as well as perspectives for future research directions.
Langerhans Cell Histiocytosis and Other Histiocytic Lesions.
McKinney R, Wang G Head Neck Pathol. 2025; 19(1):26.
PMID: 39998733 PMC: 11861498. DOI: 10.1007/s12105-025-01766-2.
The anti-leukemia activity and mechanisms of shikonin: a mini review.
Dong H, Chang C, Gao F, Zhang N, Yan X, Wu X Front Pharmacol. 2023; 14:1271252.
PMID: 38026987 PMC: 10651754. DOI: 10.3389/fphar.2023.1271252.
Milne P, Bomken S, Slater O, Kumar A, Nelson A, Roy S Blood Adv. 2022; 7(10):2171-2176.
PMID: 36112425 PMC: 10196915. DOI: 10.1182/bloodadvances.2021006732.
Genomic profiling for clinical decision making in lymphoid neoplasms.
de Leval L, Alizadeh A, Bergsagel P, Campo E, Davies A, Dogan A Blood. 2022; 140(21):2193-2227.
PMID: 36001803 PMC: 9837456. DOI: 10.1182/blood.2022015854.
Avery T, Kohler N, Zeiser R, Brummer T, Ruess D Front Oncol. 2022; 12:931774.
PMID: 35965494 PMC: 9363660. DOI: 10.3389/fonc.2022.931774.